Skip to content
lifestyle.forkstofeet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Invivyd
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
June 9, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2026
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
June 1, 2026
Invivyd to Participate in Upcoming Investor Events
May 27, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2026
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
April 20, 2026
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
April 9, 2026
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
April 7, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
Invivyd Announces Presentation at the World Vaccine Congress Washington
March 30, 2026
1
2
Next Page
→